BillionToOne Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 195

Employees
  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $125M

  • Investors
  • 34

BillionToOne General Information

Description

Developer of a molecular counter platform intended to upgrade the resolution of cell-free DNA testing. The company's prenatal testing procedure focuses on quantitative biology and statistical learning methods to optimize the signal-to-noise ratio and detect single-gene disorders, enabling expecting mothers to detect disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a simple blood test.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Laboratory Services (Healthcare)
Primary Office
  • 1035 O'brien Drive
  • Suite 1110
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

BillionToOne Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BillionToOne Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 16-Mar-2022 $125M 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series B) 14-Jun-2021 0000 000.00 00000 Completed Generating Revenue
4. Early Stage VC (Series A) 22-Feb-2021 0000 000.00 0000 Completed Generating Revenue
3. Grant 01-Jan-2018 00000 00.00 Completed Generating Revenue
2. Seed Round 30-Sep-2017 $2.5M $2.5M Completed Generating Revenue
1. Accelerator/Incubator 22-Aug-2017 Completed Startup
To view BillionToOne’s complete valuation and funding history, request access »

BillionToOne Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 000.00 000.00 00 000.00 00.000
Series B-2 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series B-1 0,000,000 00.000000 000.00 000.00 00 000.00 00.000
Series A-6 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A-5 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-4 00,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-3 000,000 00.000000 00 00 00 00 0.000
Series A-2 1,137,210 $0.000010 $0.8 $0.8 1x $0.8 2.88%
Series A-1 1,349,650 $0.000010 $0.4 $0.4 1x $0.4 3.42%
To view BillionToOne’s complete cap table history, request access »

BillionToOne Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a molecular counter platform intended to upgrade the resolution of cell-free DNA testing. The company's pre
Laboratory Services (Healthcare)
Menlo Park, CA
195 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
000000000000000000 00000000
San Francisco, CA
0000 As of 0000
00000
000000000 00000

000000

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000000000 00000000 (0000000000)
Gaithersburg, MD
000 As of 0000
0000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BillionToOne Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Invitae Formerly VC-backed San Francisco, CA 0000 00000 000000000 00000
000000 Corporate Backed or Acquired Gaithersburg, MD 000 000000&0
000000 00000000 Venture Capital-Backed San Diego, CA 00 000.00 000000000 000.00
000000 Formerly VC-backed San Carlos, CA 0000 00000 000000 - 000 00000
000000 00000000 Corporation Salt Lake City, UT 0000 00000 000000 - 000 00000
You’re viewing 5 of 8 competitors. Get the full list »

BillionToOne Patents

BillionToOne Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220010379-A1 Non-invasive prenatal testing at early stage of pregnancy Pending 07-Jul-2020 0000000000
CA-3123684-A1 Non-invasive prenatal testing at early stage of pregnancy Pending 07-Jul-2020 000000000
EP-3936626-A1 Non-invasive prenatal testing at early stage of pregnancy Pending 07-Jul-2020 000000000
EP-3936626-A4 Non-invasive prenatal testing at early stage of pregnancy Pending 07-Jul-2020 000000000
US-20210292829-A1 High throughput assays for detecting infectious diseases using capillary electrophoresis Pending 23-Mar-2020 C12Q1/701
To view BillionToOne’s complete patent history, request access »

BillionToOne Executive Team (4)

Name Title Board Seat Contact Info
Oguzhan Atay Ph.D Co-Founder, Chief Executive Officer & Chairman
Nipun Soni Chief Financial Officer
David Tsao Ph.D Co-Founder, Chief Technology Officer & Board Member
You’re viewing 3 of 4 executive team members. Get the full list »

BillionToOne Board Members (6)

Name Representing Role Since
David Tsao Ph.D BillionToOne Co-Founder, Chief Technology Officer & Board Member 000 0000
Firat Ileri Hummingbird Ventures Board Member 000 0000
Oguzhan Atay Ph.D BillionToOne Co-Founder, Chief Executive Officer & Chairman 000 0000
Swaroop Kolluri Neotribe Ventures Board Member 000 0000
Thomas Bremner Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

BillionToOne Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BillionToOne Investors (34)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adams Street Partners PE/Buyout Minority 000 0000 000000 0
Baillie Gifford Asset Manager Minority 000 0000 000000 0
Time BioVentures Venture Capital Minority 000 0000 000000 0
2c9 Ventures Venture Capital Minority 000 0000 000000 0
Four Rivers Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 34 investors. Get the full list »